Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: February 16, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 08, 2018
Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
Journal: Arthritis research & therapy
Published: September 25, 2018
No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
Journal: Seminars in arthritis and rheumatism
Published: December 13, 2017
Trial of Tocilizumab in Giant-Cell Arteritis.
Journal: The New England journal of medicine
Published: October 12, 2017
Trial of Tocilizumab in Giant-Cell Arteritis.
Journal: The New England journal of medicine
Published: July 27, 2017
Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.
Journal: Seminars in arthritis and rheumatism
Published: September 13, 2016
Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: September 07, 2016
Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.
Journal: Seminars in arthritis and rheumatism
Published: July 04, 2016
Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis.
Journal: Seminars in arthritis and rheumatism
Published: February 09, 2016
Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis.
Journal: Seminars in arthritis and rheumatism
Published: February 09, 2016
Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Journal: Annals of the rheumatic diseases
Published: April 30, 2015
Last Updated: 09/26/2026